Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Aβ) peptide in the human neuroblastoma cells

Balmiki Ray, Pradeep K. Banerjee, Nigel H. Greig, Debomoy K. Lahiri

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Memantine, an uncompetitive NMDA receptor antagonist, is a FDA-approved drug used for the treatment of moderate-to-severe Alzheimer's disease (AD). Several studies have documented protective roles of memantine against amyloid beta (Aβ) peptide-mediated damage to neurons in both in vitro and in vivo models. Memantine is also effective in reducing amyloid burden in the brain of APP transgenic mice. However, the exact mechanism by which memantine provides protection against Aβ-mediated neurodegenerative cascade, including APP metabolism, remains to be elucidated. Herein, we investigated the effect of memantine on levels of the secreted form of Aβ precursor protein (APP), secreted Aβ and cell viability markers under short/acute conditions. We treated neuronal SK-N-SH cells with 10 μM memantine and measured levels of secreted total APP (sAPP), APPα isoform and Aβ(1-40) in a time dependent manner for up to 24 h. Memantine significantly decreased the levels of the secreted form of sAPP, sAPPα and Aβ(1-40) compared to vehicle treated cells. This change started as early as 8 h and continued for up to 24 h of drug treatment. Unlike sAPP, a slight non-significant increase in total intracellular APP level was observed in 24-h treated memantine cells. Taken together, these results suggest a role for memantine in the transport or trafficking of APP molecules away from the site of their proteolytic cleavage by the secretase enzymes. Such a novel property of memantine warrants further study to define its therapeutic utility.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalNeuroscience Letters
Volume470
Issue number1
DOIs
StatePublished - Feb 5 2010

Fingerprint

Memantine
Amyloid beta-Protein Precursor
Amyloid beta-Peptides
Neuroblastoma
Amyloid Precursor Protein Secretases
Protein Precursors
Staphylococcal Protein A
N-Methyl-D-Aspartate Receptors
Amyloid
Pharmaceutical Preparations
Transgenic Mice
Cell Survival
Alzheimer Disease
Protein Isoforms

Keywords

  • Alzheimer's drug
  • Amyloid
  • beta-Peptide
  • Dementia
  • Neuronal cells
  • Protein processing
  • sAPP
  • Secretase
  • Tissue culture

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Aβ) peptide in the human neuroblastoma cells. / Ray, Balmiki; Banerjee, Pradeep K.; Greig, Nigel H.; Lahiri, Debomoy K.

In: Neuroscience Letters, Vol. 470, No. 1, 05.02.2010, p. 1-5.

Research output: Contribution to journalArticle

@article{df8565f6bb0b4d138bbb646a7873b25a,
title = "Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Aβ) peptide in the human neuroblastoma cells",
abstract = "Memantine, an uncompetitive NMDA receptor antagonist, is a FDA-approved drug used for the treatment of moderate-to-severe Alzheimer's disease (AD). Several studies have documented protective roles of memantine against amyloid beta (Aβ) peptide-mediated damage to neurons in both in vitro and in vivo models. Memantine is also effective in reducing amyloid burden in the brain of APP transgenic mice. However, the exact mechanism by which memantine provides protection against Aβ-mediated neurodegenerative cascade, including APP metabolism, remains to be elucidated. Herein, we investigated the effect of memantine on levels of the secreted form of Aβ precursor protein (APP), secreted Aβ and cell viability markers under short/acute conditions. We treated neuronal SK-N-SH cells with 10 μM memantine and measured levels of secreted total APP (sAPP), APPα isoform and Aβ(1-40) in a time dependent manner for up to 24 h. Memantine significantly decreased the levels of the secreted form of sAPP, sAPPα and Aβ(1-40) compared to vehicle treated cells. This change started as early as 8 h and continued for up to 24 h of drug treatment. Unlike sAPP, a slight non-significant increase in total intracellular APP level was observed in 24-h treated memantine cells. Taken together, these results suggest a role for memantine in the transport or trafficking of APP molecules away from the site of their proteolytic cleavage by the secretase enzymes. Such a novel property of memantine warrants further study to define its therapeutic utility.",
keywords = "Alzheimer's drug, Amyloid, beta-Peptide, Dementia, Neuronal cells, Protein processing, sAPP, Secretase, Tissue culture",
author = "Balmiki Ray and Banerjee, {Pradeep K.} and Greig, {Nigel H.} and Lahiri, {Debomoy K.}",
year = "2010",
month = "2",
day = "5",
doi = "10.1016/j.neulet.2009.11.016",
language = "English (US)",
volume = "470",
pages = "1--5",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Aβ) peptide in the human neuroblastoma cells

AU - Ray, Balmiki

AU - Banerjee, Pradeep K.

AU - Greig, Nigel H.

AU - Lahiri, Debomoy K.

PY - 2010/2/5

Y1 - 2010/2/5

N2 - Memantine, an uncompetitive NMDA receptor antagonist, is a FDA-approved drug used for the treatment of moderate-to-severe Alzheimer's disease (AD). Several studies have documented protective roles of memantine against amyloid beta (Aβ) peptide-mediated damage to neurons in both in vitro and in vivo models. Memantine is also effective in reducing amyloid burden in the brain of APP transgenic mice. However, the exact mechanism by which memantine provides protection against Aβ-mediated neurodegenerative cascade, including APP metabolism, remains to be elucidated. Herein, we investigated the effect of memantine on levels of the secreted form of Aβ precursor protein (APP), secreted Aβ and cell viability markers under short/acute conditions. We treated neuronal SK-N-SH cells with 10 μM memantine and measured levels of secreted total APP (sAPP), APPα isoform and Aβ(1-40) in a time dependent manner for up to 24 h. Memantine significantly decreased the levels of the secreted form of sAPP, sAPPα and Aβ(1-40) compared to vehicle treated cells. This change started as early as 8 h and continued for up to 24 h of drug treatment. Unlike sAPP, a slight non-significant increase in total intracellular APP level was observed in 24-h treated memantine cells. Taken together, these results suggest a role for memantine in the transport or trafficking of APP molecules away from the site of their proteolytic cleavage by the secretase enzymes. Such a novel property of memantine warrants further study to define its therapeutic utility.

AB - Memantine, an uncompetitive NMDA receptor antagonist, is a FDA-approved drug used for the treatment of moderate-to-severe Alzheimer's disease (AD). Several studies have documented protective roles of memantine against amyloid beta (Aβ) peptide-mediated damage to neurons in both in vitro and in vivo models. Memantine is also effective in reducing amyloid burden in the brain of APP transgenic mice. However, the exact mechanism by which memantine provides protection against Aβ-mediated neurodegenerative cascade, including APP metabolism, remains to be elucidated. Herein, we investigated the effect of memantine on levels of the secreted form of Aβ precursor protein (APP), secreted Aβ and cell viability markers under short/acute conditions. We treated neuronal SK-N-SH cells with 10 μM memantine and measured levels of secreted total APP (sAPP), APPα isoform and Aβ(1-40) in a time dependent manner for up to 24 h. Memantine significantly decreased the levels of the secreted form of sAPP, sAPPα and Aβ(1-40) compared to vehicle treated cells. This change started as early as 8 h and continued for up to 24 h of drug treatment. Unlike sAPP, a slight non-significant increase in total intracellular APP level was observed in 24-h treated memantine cells. Taken together, these results suggest a role for memantine in the transport or trafficking of APP molecules away from the site of their proteolytic cleavage by the secretase enzymes. Such a novel property of memantine warrants further study to define its therapeutic utility.

KW - Alzheimer's drug

KW - Amyloid

KW - beta-Peptide

KW - Dementia

KW - Neuronal cells

KW - Protein processing

KW - sAPP

KW - Secretase

KW - Tissue culture

UR - http://www.scopus.com/inward/record.url?scp=74149089703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74149089703&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2009.11.016

DO - 10.1016/j.neulet.2009.11.016

M3 - Article

C2 - 19948208

AN - SCOPUS:74149089703

VL - 470

SP - 1

EP - 5

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1

ER -